



Search for...



ORIGINAL INVESTIGATION | VOLUME 82, ISSUE 4, P454-463, OCTOBER 2023

 Download Full Issue

Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes

Elaine Ku   • Charles E. McCulloch • Timothy P. Copeland • Lesley A. Inker • Hocine Tighiouart •

Mark J. Sarnak

Published: June 01, 2023 • DOI: <https://doi.org/10.1053/j.ajkd.2023.03.013> •

Check for updates



PlumX Metrics

Rationale & Objective

Acute decreases in glomerular filtration rate (GFR) occur commonly during intensive blood pressure (BP) lowering. Our objective was to determine the relationship between acute decreases in estimated GFR and patient outcomes.

Study Design

Retrospective observational study.



ig & Participants



Participants from 4 randomized controlled trials of intensive BP lowering in chronic kidney disease (Modification of Diet in Renal Disease study, African American Study of Kidney Disease and Hypertension, Systolic Blood Pressure Intervention Trial, and Action to Control Cardiovascular Risk in Diabetes trial).

Exposure

A 4-category exposure defined by the level of acute decrease in estimated GFR (defined as $>15\%$ vs $\leq 15\%$ between baseline and month 4) and the randomization to intensive versus usual BP control.

Outcomes

Risk of kidney replacement therapy (primary outcome), defined as the need for dialysis or transplant except in the Action to Control Cardiovascular Risk in Diabetes trial, which defined its kidney outcome as a composite occurrence of serum creatinine concentration >3.3 mg/dL, kidney failure, or kidney replacement therapy.

Analytical Approach

Multivariable Cox models.

Results

We included 4,473 individuals randomly assigned to intensive versus usual BP control who had a total of 351 kidney outcomes and 304 deaths during median follow-up durations of 22 and 24 months, respectively. Approximately 14% of participants exhibited an acute decrease in eGFR, 11.0% in the usual BP treatment arm and 17.8% in the intensive BP treatment arm. In adjusted models, compared with a $\leq 15\%$ eGFR decrease in the usual BP arm, a $\leq 15\%$ eGFR decrease in the intensive BP control arm was associated with lower risk of the kidney outcome (HR, 0.75; 95% CI, 0.57-0.98). In contrast, a $>15\%$ decrease in eGFR was associated with a higher risk of the kidney outcome in the usual (HR, 2.47; 95% CI, 1.80-3.38) and intensive BP treatment arms (HR, 1.99; 95% CI, 1.45-2.73) compared with a $\leq 15\%$ decrease in the usual BP arm.

Limitations

Observational study, residual confounding.

Conclusions

Decreases in eGFR of $>15\%$ in the usual and intensive BP treatment arms were associated with a higher risk of kidney outcomes compared with a $\leq 15\%$ decrease in the usual BP arm and may be a harbinger of adverse outcomes.



Index Words

[hypertension](#) • [chronic kidney disease](#) • [end-stage kidney disease](#)

To read this article in full you will need to make a payment

Purchase one-time access:

Academic & Personal: 24 hour online access

Corporate R&D Professionals: 24 hour online access

[NKF Member Login](#)

NKF Members: Full access to the journal is a member benefit. Login via the [NKF Website](#) to access all journal content and features.

Subscribe:

Subscribe to *American Journal of Kidney Diseases*

Already a print subscriber? [Claim online access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to ScienceDirect](#)

References

1. Wright Jr., J.T. • Williamson J.D. • Whelton P.K. • et al.
A randomized trial of intensive versus standard blood-pressure control.
N Engl J Med. 2015; **373**: 2103-2116
<https://doi.org/10.1056/nejmoa1511939>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)



2. Cheung A.K. • Rahman M. • Reboussin D.M. • et al.
Effects of intensive BP control in CKD.
J Am Soc Nephrol. 2017; **28**: 2812-2823
<https://doi.org/10.1681/asn.2017020148>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
3. Tomson C.R.V. • Cheung A.K. • Mann J.F.E. • et al.
Management of blood pressure in patients with chronic kidney disease not receiving dialysis: synopsis of the 2021 KDIGO Clinical Practice Guideline.
Ann Intern Med. 2021; **174**: 1270-1281
<https://doi.org/10.7326/m21-0834>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
4. Cheung A.K. • Chang T.I. • Cushman W.C. • et al.
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease.
Kidney Int. 2021; **99**: 559-569
<https://doi.org/10.1016/j.kint.2020.10.026>

[View in Article](#) ^

[Scopus \(118\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
5. Whelton P.K. • Carey R.M. • Aronow W.S. • et al.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Hypertension. 2018; **71**: e13-e115
<https://doi.org/10.1161/hyp.0000000000000065>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)
6. Holtkamp F.A. • de Zeeuw D. • Thomas M.C. • et al.

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Kidney Int. 2011; **80**: 282-287

<https://doi.org/10.1038/ki.2011.79>

[View in Article](#) ^

[Scopus \(271\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

7. Christensen P.K. • Hansen H.P. • Parving H.H.
Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients.

Kidney Int. 1997; **52**: 1369-1374

<https://doi.org/10.1038/ki.1997.463>

[View in Article](#) ^

[Scopus \(97\)](#) • [PubMed](#) • [Abstract](#) • [Full Text PDF](#) • [Google Scholar](#)

8. **Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study.**

J Am Soc Nephrol. 1996; **7**: 2097-2109

<https://doi.org/10.1681/asn.v7102097>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

9. Palmer B.F.
Renal dysfunction complicating the treatment of hypertension.

N Engl J Med. 2002; **347**: 1256-1261

<https://doi.org/10.1056/nejmra020676>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

10. Ku E. • Bakris G. • Johansen K.L. • et al.
Acute declines in renal function during intensive BP lowering: implications for future ESRD risk.

J Am Soc Nephrol. 2017; **28**: 2794-2801

<https://doi.org/10.1681/asn.2017010040>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

11. Remuzzi G. • Perico N. • Macia M. • Ruggenenti P.
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Kidney Int Suppl. 2005; : S57-S65

<https://doi.org/10.1111/j.1523-1755.2005.09911.x>

[View in Article](#) ^

[Scopus \(377\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

12. Bakris G.L. • Weir M.R.
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?.

Arch Intern Med. 2000; **160**: 685-693

<https://doi.org/10.1001/archinte.160.5.685>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

13. Townsend R.R.
Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.

UptoDate, vol. 38. 2023; (Updated July 11, 2022)

<https://www.uptodate.com/contents/major-side-effects-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers>

Date accessed: February 14, 2023

[View in Article](#) ^

[Google Scholar](#)

14. Malhotra R. • Craven T. • Ambrosius W.T. • et al.
Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT.

Am J Kidney Dis. 2019; **73**: 21-30

<https://doi.org/10.1053/j.ajkd.2018.07.015>

[View in Article](#) ^

[Scopus \(83\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

15. Nadkarni G.N. • Chauhan K. • Rao V. • et al.

Effect of intensive blood pressure lowering on kidney tubule injury: findings from the ACCORD trial study participants.

Am J Kidney Dis. 2019; **73**: 31-38

<https://doi.org/10.1053/j.ajkd.2018.07.016>

[View in Article](#) ^

[Scopus \(39\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

16. Ku E. • McCulloch C.E. • Vittinghoff E. • Lin F. • Johansen K.L.

Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

J Am Heart Assoc. 2018; 7e009992

<https://doi.org/10.1161/jaha.118.009992>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

17. Bhandari S. • Ives N. • Brettell E.A. • et al.

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Nephrol Dial Transplant. 2016; **31**: 255-261

<https://doi.org/10.1093/ndt/gfv346>

[View in Article](#) ^

[Scopus \(83\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

18. Murphy D.P. • Drawz P.E. • Foley R.N.

Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States.

J Am Soc Nephrol. 2019; **30**: 1314-1321

<https://doi.org/10.1681/asn.2018100971>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

19. Weir M.R. • Chen D.C. • Ku E.

Should renin-angiotensin system blockade be avoided in patients with declining kidney function?.

Am J Kidney Dis. 2020; **76**: 739-741

<https://doi.org/10.1053/j.ajkd.2020.04.003>

[View in Article](#) ^

[Scopus \(3\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

20. Schrier R. • McFann K. • Johnson A. • et al.

Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

J Am Soc Nephrol. 2002; **13**: 1733-1739

<https://doi.org/10.1097/01.asn.0000018407.60002.b9>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

21. Howard B.V. • Roman M.J. • Devereux R.B. • et al.

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial.

JAMA. 2008; **299**: 1678-1689

<https://doi.org/10.1001/jama.299.14.1678>

[View in Article](#) ^

[Scopus \(210\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

22. Zhang W. • Zhang S. • Deng Y. • et al.

Trial of intensive blood-pressure control in older patients with hypertension.

N Engl J Med. 2021; **385**: 1268-1279

<https://doi.org/10.1056/nejmoa2111437>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)



23. Ruggenenti P. • Perna A. • Loriga G. • et al.
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
Lancet. 2005; **365**: 939-946
[https://doi.org/10.1016/S0140-6736\(05\)71082-5](https://doi.org/10.1016/S0140-6736(05)71082-5)
[View in Article](#) ^
[Scopus \(539\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
24. Klahr S. • Levey A.S. • Beck G.J. • et al.
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
N Engl J Med. 1994; **330**: 877-884
<https://doi.org/10.1056/nejm199403313301301>
[View in Article](#) ^
[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
25. Agodoa L.Y. • Appel L. • Bakris G.L. • et al.
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
JAMA. 2001; **285**: 2719-2728
<https://doi.org/10.1001/jama.285.21.2719>
[View in Article](#) ^
[Scopus \(878\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
26. Wright Jr., J.T. • Bakris G. • Greene T. • et al.
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
JAMA. 2002; **288**: 2421-2431
<https://doi.org/10.1001/jama.288.19.2421>
[View in Article](#) ^
[Scopus \(1685\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
27. Cushman W.C. • Evans G.W. • et al. • ACCORD Group

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

N Engl J Med. 2010; **362**: 1575-1585

<https://doi.org/10.1056/nejmoa1001286>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

28. Inker L.A. • Eneanya N.D. • Coresh J. • et al.

New creatinine- and cystatin C-based equations to estimate GFR without race.

N Engl J Med. 2021; **385**: 1737-1749

<https://doi.org/10.1056/NEJMoa2102953>

[View in Article](#) ^

[Scopus \(743\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

29. Collard D. • Brouwer T.F. • Olde Engberink R.H.G. • Zwinderman A.H. • Vogt L. • van den Born B.J.H.

Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy.

Hypertension. 2020; **75**: 1205-1212

<https://doi.org/10.1161/hypertensionaha.119.14659>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

30. Ku E. • Ix J.H. • Jamerson K. • et al.

Acute declines in renal function during intensive bp lowering and long-term risk of death.

J Am Soc Nephrol. 2018; **29**: 2401-2408

<https://doi.org/10.1681/ASN.2018040365>

[View in Article](#) ^

[Scopus \(12\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

31. Clase C.M. • Barzilay J. • Gao P. • et al.

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.

Kidney Int. 2017; **91**: 683-690

<https://doi.org/10.1016/j.kint.2016.09.038>

[View in Article](#) 

[Scopus \(59\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

32. Sumida K. • Nadkarni G.N. • Grams M.E. • et al.

Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis.

Ann Intern Med. 2020; **173**: 426-435

<https://doi.org/10.7326/m20-0529>

[View in Article](#) 

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

33. Linden A. • Mathur M.B. • VanderWeele T.J.

Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: the evalua package.

Stata J. 2020; **20**: 162-175

<https://doi.org/10.1177/1536867X20909696>

[View in Article](#) 

[Scopus \(49\)](#) • [Crossref](#) • [Google Scholar](#)

34. VanderWeele T.J. • Mathur M.B.

Commentary: developing best-practice guidelines for the reporting of E-values.

Int J Epidemiol. 2020; **49**: 1495-1497

<https://doi.org/10.1093/ije/dyaa094>

[View in Article](#) 

[Scopus \(55\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

35. Griffin K.A.

Hypertensive kidney injury and the progression of chronic kidney disease.

Hypertension. 2017; **70**: 687-694

[View in Article](#) 

[Scopus \(67\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)



36. Hamming I. • Goor H. • Navis G.J.

ACE inhibitor use and the increased long-term risk of renal failure in diabetes.

Kidney Int. 2006; **70**: 1377-1378

<https://doi.org/10.1038/sj.ki.5001684>

[View in Article](#) ^

[Scopus \(8\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

37. Hamming I. • Navis G. • Kocks M.J. • van Goor H.

ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats.

J Pathol. 2006; **209**: 129-139

<https://doi.org/10.1002/path.1956>

[View in Article](#) ^

[Scopus \(47\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

38. Weir M.R.

Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.

Kidney Int. 2017; **91**: 529-531

<https://doi.org/10.1016/j.kint.2016.11.019>

[View in Article](#) ^

[Scopus \(14\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

39. Goraya T.Y. • Leibson C.L. • Palumbo P.J. • et al.

Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study.

J Am Coll Cardiol. 2002; **40**: 946-953

[https://doi.org/10.1016/s0735-1097\(02\)02065-x](https://doi.org/10.1016/s0735-1097(02)02065-x)

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

40. Gambaro A. • Lombardi G. • Ribichini F.L. • Mantovani A. • Bignamini A.A. •
Gambaro G.

Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcom



systematic review and meta-analysis.
J Hypertens. 2022; **40**: 413-421
<https://doi.org/10.1097/hjh.0000000000003066>

[View in Article](#) ^
[PubMed](#) • [Crossref](#) • [Google Scholar](#)

Article info

Publication history

Published online: June 01, 2023

Footnotes

Complete author and article information provided before references.

Identification

DOI: <https://doi.org/10.1053/j.ajkd.2023.03.013>

Copyright

© 2023 by the National Kidney Foundation, Inc.

ScienceDirect

[Access this article on ScienceDirect](#)

Related Articles

Home	Plain-Language Summaries	Atlas of Renal Pathology (Free)	Quiz (Free)	AJKD 40th Anniversary
ARTICLES & ISSUES	Supplements	Core Curriculum (Free)	Reviews	40th Anniversary Special Collection: CKD
Current Issue	KDOQI Guidelines	In a Few Words (Free)	Teaching Cases	40th Anniversary Special Collection: CKD
Articles in Press	USRDS	In Practice	World Kidney Forum (Free)	40th Anniversary Special Collection: Dialysis
List of Issues	SECTIONS	Policy Forum	COLLECTIONS	

40th Anniversary Special Collection: Kidney Transplantation	Kidney Transplantation	Open Access Information	Editorial Board	Join NKF
Acute Kidney Injury	NKF SCM Highlights from AJKD	Researcher Academy	Free Sample Issue	NKF Journals
AJKD Editors' Choice Articles	Open Access	Author Rights	Journal Metrics	NKF Spring Clinical Meetings
Cardiorenal	Patient-Centered Research	JOURNAL INFO	New Content Alerts	NKF for Professionals
COVID-19 Resource Collection	Pregnancy and Kidney Disease	About the Journal	Permissions Requests	NKF for Patients
Diabetes and Kidney Disease	World Kidney Day	About NKF	Abstracting/Indexing	Press Inquiries
Highly Cited	FOR AUTHORS	Member Access	Information for Advertisers	Submit Your Manuscript
Health Disparities in Kidney Disease	Submit Article	Activate Online Access	NKF	FOLLOW US
Home Dialysis	Guide for Authors	AJKD Editorial Internship Program	About NKF	Facebook
	Aims & Scope	AJKD Reviewer Hall of Fame	About NKF Member Access	Twitter
	AJKD Express	Contact Us		<i>AJKD</i> Blog

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie 設定](#) for this site.

All content on this site: Copyright © 2023 Elsevier Inc., its licensors, and contributors.
All rights are reserved, including those for text and data mining, AI training, and similar technologies.
For all open access content, the Creative Commons licensing terms apply.

[Privacy Policy](#) [Terms and Conditions](#) [Accessibility](#) [Help & Contact](#)

